Please see below some recent investor relations related coverage on ANP:
Investor Webinar – October 2020
Standing up for boys that can’t - ****** TV Interview
The role of diagnostics in COVID-19 - Livewire | Claire Aitchison - The role of diagnostics in COVID-19
Meet the ASX-listed biotech tapping into unclaimed medical territory - Switzer Daily | Sophia Katsinas
Melbourne-based biotech submits Duchenne Muscular Dystrophy drug for US and EU Orphan Drug designation - Switzer Daily | Sophia Katsinas
Antisense’s DMD drug could have ‘profound’ impact on boys - * | Derek Rose -
Antisense Therapeutics’ FDA ruling could be worth ‘hundreds of millions’ - * | Derek Rose
Antisense Therapeutics (ASX:ANP) sees further improvement with ATL1102 - The Market Herald | Lisa Simcock
Antisense Eyes A Golden Ticket In The US - ********* | Tim Boreham
Go it alone or do a deal??, page-38
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.002(2.47%) |
Mkt cap ! $81.90M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.1¢ | 7.8¢ | $1.034M | 12.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 349999 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 305419 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |